Journal of Clinical Oncology
Articles in this Issue
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies
Advances in systemic therapy have improved outcomes for metastatic non–small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, sur...
The Liver We Share
A medical student's first encounter with a hepatectomy comes full circle when he becomes a living liver donor for his wife with metastatic pancreatic cancer, reshaping his understanding of medicine as...
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP
PURPOSE Mismatch repair deficiency (dMMR) or microsatellite instability (MSI) represents a distinct phenotype among solid tumors resulting in the generation of highly immunogenic n...
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease
PURPOSE Chronic graft-versus-host disease (cGVHD) is a multisystem alloimmune disorder associated with abnormal B-cell biology and aberrant antibody responses. As B-cell–directed t...
Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT0314168...
Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer
Enhancing Delivery of Tobacco Treatment in Oncology Care: Moving the Needle
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
The phase III AUGMENT trial (ClinicalTrials.gov identifier: NCT01938001 ) demonstrated improved efficacy for lenalidomide plus rituximab (R...
Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer
National Quality Improvement Initiative to Increase Smoking Cessation Assistance in Commission on Cancer Programs and National Accreditation Program for Breast Centers
PURPOSE Smoking cessation after a cancer diagnosis improves survival, but widespread adoption of evidence-based cessation assistance has not been demonstrated. American College of...
Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy
Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non–Muscle-Invasive Bladder Cancer Progress or Overreach?
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
PURPOSE To evaluate the efficacy and safety of adding tislelizumab to induction chemotherapy and concurrent chemoradiotherapy (CRT), with or without maintenance immunotherapy, in p...